[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

BridgeBio Pharma Form 144 Notice filed on June 28, 2025, details a proposed sale of securities by Denis Von Kaeppler IRA Rollover, who is related to the company through their wife's Board of Directors position.

Key transaction details:

• Securities to be sold: 1,891 shares of common stock
• Aggregate market value: $83,261.30
• Planned sale date: June 26, 2025 on NASDAQ
• Broker: Morgan Stanley Smith Barney LLC

The shares were originally acquired through an open market purchase on December 28, 2021. Notable recent insider activity includes multiple sales by Hannah Valantine, who sold a total of 17,168 shares for approximately $686,334 in gross proceeds on June 10, 2025. The company has approximately 189.9 million shares outstanding.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001855608
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BRIDGEBIO PHARMA, INC.
SEC File Number	001-38959
Address of Issuer	3160 Porter Drive Suite 250 Palo Alto CALIFORNIA 94304
Phone	(650) 391-9740
Name of Person for Whose Account the Securities are To Be Sold	DENIS VON KAEPPLER IRA ROLLOVER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	client's wife is a BoD

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1891	83261.30	189880720	06/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/28/2021	Open Market Purchase	Open Market			1891	12/28/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
HANNAH A VALANTINE 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	06/10/2025	4292	171680.00

144: Remarks and Signature

Remarks
Date of Notice	06/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Valantine Hannah
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of BBIO stock are being sold according to the June 2025 Form 144 filing?

According to the Form 144 filing, 1,891 shares of BBIO common stock are proposed to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $83,261.30.

Who is selling BBIO shares in this Form 144 filing from June 2025?

The securities are to be sold by DENIS VON KAEPPLER IRA ROLLOVER, who has a relationship to BridgeBio Pharma where the client's wife is a member of the Board of Directors.

What was Hannah Valantine's recent trading activity in BBIO stock?

According to the filing, Hannah Valantine sold multiple blocks of BBIO shares on June 10, 2025. Specifically, she executed three sales of 4,292 shares each, with gross proceeds of $171,551.24 per transaction, plus an additional sale of 4,292 shares for $171,680.00.

What is the total number of outstanding BBIO shares as of June 2025?

According to the Form 144 filing, BridgeBio Pharma (BBIO) had 189,880,720 shares outstanding at the time of the filing in June 2025.

When did the Form 144 seller originally acquire their BBIO shares?

The shares were acquired on December 28, 2021 through an open market purchase transaction, with cash payment made on the same date.